Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRX-818 in advanced cancer
NCT02507544Phase 1Completed
- Sponsor
- TaiRx, Inc.
- Start
- Sep 2015
- Primary completion
- Apr 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dasatinib in cancer, sponsored by TaiRx, Inc. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Started Sep 2015; status: completed.
02
Drugs
dasatinib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02507544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02507544.